MiniMed has won FDA clearance for MiniMed Fit, a tubeless insulin pump that gives the company its first tubeless version of automated insulin delivery. The device is designed for up to seven days of wear, holds 300 units of insulin and is controlled through a smartphone application.

The clearance expands MiniMed’s insulin delivery portfolio at a time when tubeless systems are becoming a more contested segment. It also creates a new commercial test for the company after its recent separation from Medtronic’s diabetes business.

Product and launch setup

MiniMed said the Fit system uses a 300-unit insulin cartridge integrated into a disposable, wearable patch rather than a separate, refillable cartridge inserted into a reusable pump. The company said the design reduces the number of pump changes and simplifies daily diabetes management decisions.

A phased U.S. launch is expected to begin in spring 2027, following an early customer experience phase expected to begin in MiniMed’s fourth quarter of fiscal year 2027. MiniMed said it has been building manufacturing capacity and commercial infrastructure alongside the regulatory process, and plans to “significantly” expand manufacturing capacity as commercialization progresses.

Chief Executive Officer Que Dallara said the device cleared FDA ahead of schedule and added that distribution through the pharmacy channel should make it easier to obtain.

The market signal

The timing is notable because the announcement came just days after Tandem Diabetes Care said it had received FDA clearance for Tandem Mobi, another tubeless insulin delivery device. While both rely on insulin cartridge technology, MiniMed Fit’s fully integrated disposable patch is a distinct design choice that could shape convenience, replacement patterns and manufacturing economics.

For MiniMed, the clearance adds to a year of corporate milestones. The company said it closed its Nasdaq IPO in March, raising $560 million in gross proceeds, while Medtronic retained about 90% ownership after the offering. With Fit, the next question is less about novelty than execution: whether MiniMed can translate clearance, manufacturing buildout and pharmacy-channel access into adoption once the rollout starts.